Expert Interviews

Tiffany Sia, MD, Provides Rationale for Exploring Interventions for Oligoprogressive Disease in Gynecologic Malignancies Treated With ICI
September 30, 2022

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
September 29, 2022

Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.

Treating Patients with High-Risk NDMM
September 29, 2022

The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.

Tazemetostat in R/R FL: Original Trial Data and a Propensity Score-Matched Analysis
September 29, 2022

Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.

Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
September 28, 2022

Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.

Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
September 28, 2022

An oncologist muses on the potential of real-world data in evaluating the use of a quadruplet regimen for newly diagnosed transplant-eligible multiple myeloma.

Joel W. Neal, MD, PhD Discusses the Data on Cabozantinib and Atezolizumab Use in Advanced NSCLC
September 28, 2022

In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.